Physician profile
Thomas E Lockard
NPI 1669405593
$2,380.74
in general payments reported to CMS, 2019-2025
26 companies · $30.76 in 2025
The $30.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,666 · 2020: $498 · 2021: $12.46 · 2022: $41.96 · 2023: $132 · 2025: $30.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $241.64 | 2019-2020 | |
| Amarin Pharma, INC. | $224.54 | 2019-2020 | |
| Abbvie INC. | $205.17 | 2021-2025 | |
| Amgen INC. | $185.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $144.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.50 | 2019-2020 | |
| Astellas Pharma US INC | $86.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.50 | 2019 | |
| Allergan, INC. | $82.13 | 2019-2020 | |
| Horizon Therapeutics Plc | $71.37 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $66.53 | 2019 | |
| Glaxosmithkline, LLC. | $62.80 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $44.61 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.49 | 2019-2020 | |
| Redhill Biopharma INC. | $24.55 | 2020 | |
| Lilly USA, LLC | $22.12 | 2019 | |
| Grifols USA, LLC | $19.24 | 2019 | |
| Mylan Specialty L.P. | $17.66 | 2019 | |
| Aytu Biopharma, INC. | $16.57 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2019 | |
| Gilead Sciences, INC. | $12.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lockard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.